글로벌 델타형 간염 바이러스(HDV) 감염 시장 – 2031년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

글로벌 델타형 간염 바이러스(HDV) 감염 시장 – 2031년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Nov 2024
  • Global
  • 350 Pages
  • 테이블 수: 703
  • 그림 수: 61

Global Hepatitis Delta Virus Hdv Infection Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2024 –2031
Diagram 시장 규모(기준 연도)
USD 47.34 Million
Diagram 시장 규모(예측 연도)
USD 68.24 Million
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>글로벌 델타형 간염 바이러스(HDV) 감염 시장, 유형별(급성 D형 간염 및 만성 D형 간염), 치료(수술( 간 이식 ) 및 약물), 약물 유형(브랜드 및 제네릭), 투여 경로(경구 및 비경구), 연령대(성인, 노인 및 소아), 성별(여성 및 남성), 전염(오염된 바늘, 감염된 혈액 노출, 혈액 및 혈장 제품 수혈 및 기타), 최종 사용자(병원, 전문 클리닉, 가정 간병 시설, 연구 기관 및 학술 센터, 외래 수술 센터 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) - 2031년까지의 산업 동향 및 예측

델타형 간염 바이러스(HDV) 감염 시장

델타형 간염 바이러스(HDV) 감염 시장 분석 및 통찰력

간염, 특히 B형 간염의 유병률이 증가함에 따라 글로벌 델타 간염 바이러스(HDV) 감염 시장에 상당한 영향을 미치고 있습니다. D형 간염은 D형 간염 바이러스(HDV)로 인한 간 감염으로, 복제를 위해 B형 간염 바이러스(HBV)가 필요합니다. B형 간염 감염이 전 세계적으로 증가함에 따라 HDV 감염에 취약한 개인 수도 증가합니다. HBV에 감염된 개인이 늘어나면서 HDV의 표적 인구가 늘어나 HDV에 특화된 진단 및 치료 솔루션에 대한 수요가 증가합니다.

델타형 간염 바이러스(HDV) 감염 시장델타형 간염 바이러스(HDV) 감염 시장

Data Bridge Market Research에 따르면 글로벌 델타 간염 바이러스(HDV) 감염 시장 규모는 2023년 4,734만 달러에서 2031년 6,824만 달러로 성장할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 4.8%로 성장할 것으로 예상됩니다.

보고서 메트릭

세부

예측 기간

2024년부터 2031년까지

기준 연도

2023

역사적 연도

2022 (2016-2021년까지 사용자 정의 가능)

양적 단위

수익 (단위: USD 백만)

다루는 세그먼트

유형(급성 D형 간염 및 만성 D형 간염), 치료(수술(간 이식) 및 약물), 약물 유형(브랜드 및 제네릭), 투여 경로(경구 및 비경구), 연령대(성인, 노인 및 소아), 성별(여성 및 남성), 전염(오염된 바늘, 감염된 혈액 노출, 혈액 및 혈장 제품 수혈 및 기타), 최종 사용자(병원, 전문 클리닉, 가정 간병 시설, 연구 기관 및 학술 센터, 외래 수술 센터 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타)

적용 국가

미국, 캐나다, 멕시코, 독일, 프랑스, ​​영국, 이탈리아, 스페인, 네덜란드, 스위스, 러시아, 벨기에, 터키, 덴마크, 스웨덴, 폴란드, 노르웨이, 핀란드, 유럽의 나머지 지역, 중국, 일본, 인도, 한국, 호주, 태국, 말레이시아, 인도네시아, 싱가포르, 필리핀, 뉴질랜드, 베트남, 대만, 아시아 태평양의 나머지 지역, 브라질, 아르헨티나, 남미의 나머지 지역, 남아프리카, 사우디 아라비아, UAE, 이집트, 바레인, 쿠웨이트, 오만, 카타르, 중동 및 아프리카의 나머지 지역

시장 참여자 포함

GILEAD SCIENCES, INC., GENENTECH, INC., ALNYLAM PHARMACEUTICALS, INC., ASSEMBLY BIOSCIENCES, INC., EIGER BIOPHARMACEUTICALS, GLOBEIMMUNE INC., HUAHUI HEALTH LTD., JOHNSON & JOHNSON SERVICES, INC., PHARMAESSENTIA CORPORATION, REPLICOR, VIR BIOTECHNOLOGY, INC.

시장 정의

델타 간염(HDV) 감염은 델타 간염 바이러스(HDV)가 이미 B형 간염 바이러스(HBV)에 감염된 간을 감염시킬 때 발생하는 드물지만 심각한 형태의 바이러스성 간염입니다. HDV는 HBV가 복제하고 새로운 바이러스 입자를 생성해야 하는 결함이 있는 바이러스이며, 급성 간염, 간부전, 심지어 사망을 포함한 간 질환을 빠르게 유발하는 능력이 특징입니다. HBV와 HDV의 동시 감염은 HBV 단독 감염에 비해 간 질환의 더 심각하고 빠른 진행으로 이어지며, 종종 더 높은 수준의 간 염증과 섬유증과 관련이 있습니다.

글로벌 델타형 간염 바이러스(HDV) 감염 시장 역학

이 섹션에서는 시장 동인, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.      

운전자

  • 간염 유병률 증가

간염, 특히 B형 간염의 유병률이 증가함에 따라 글로벌 델타 간염 바이러스(HDV) 감염 시장에 상당한 영향을 미치고 있습니다. D형 간염은 D형 간염 바이러스(HDV)로 인한 간 감염으로, 복제를 위해 B형 간염 바이러스(HBV)가 필요합니다. B형 간염 감염이 전 세계적으로 증가함에 따라 HDV 감염에 취약한 개인 수도 증가합니다. HBV에 감염된 개인이 늘어나면서 HDV의 표적 인구가 늘어나 HDV에 특화된 진단 및 치료 솔루션에 대한 수요가 증가합니다.

  • 의료비 지출 증가

의료비 지출 증가는 진단 기술과 치료 옵션에 대한 보다 많은 투자를 촉진함으로써 글로벌 델타형 간염 바이러스(HDV) 감염 시장의 성장에 상당한 영향을 미칩니다. 의료 예산이 확대됨에 따라 정부와 의료 기관은 HDV에 대한 고급 진단 도구에 더 많은 리소스를 할당할 수 있습니다. 이 투자는 보다 민감하고 정확한 검사 방법의 개발 및 배포로 이어져 조기 발견율을 높이고 진단 서비스에 대한 수요를 증가시킵니다. 고품질 진단 검사의 가용성이 향상되면 전반적인 검사 및 스크리닝 활동이 증가하여 시장 성장에 직접 기여합니다. 게다가, 더 높은 의료비는 종종 HDV에 대한 치료 옵션에 대한 접근성과 경제성으로 이어집니다. 자금이 증가함에 따라 혁신적인 항바이러스 요법 및 기타 의료 개입의 개발 및 배포에 대한 잠재력이 커집니다. 효과적인 치료에 대한 이러한 확대된 접근성은 환자 결과를 개선할 뿐만 아니라 치료 옵션을 찾는 보다 광범위한 환자 기반을 만들어 시장 성장을 자극합니다. 향상된 치료 옵션은 더 나은 질병 관리와 더 높은 치료 준수율로 이어져 HDV 감염 시장 내 수요를 더욱 증가시킬 수 있습니다.

델타형 간염 바이러스(HDV) 감염 시장

기회

  • 혁신적 약물 개발의 증가

JNJ-73763989 및 페긴터페론 람다와 같은 파이프라인 치료법은 제약 회사가 이 분야에서 효과적인 치료법에 대한 충족되지 않은 상당한 수요를 해결할 수 있는 새로운 기회를 창출하고 있습니다. JNJ-73763989는 바이러스 수명 주기의 필수 구성 요소를 표적으로 삼아 HDV 복제를 억제하도록 설계된 획기적인 치료법으로, 기존 치료법에 비해 더 정확하고 잠재적으로 효과적인 접근 방식을 제공합니다. 반면, 인터페론 치료법의 새로운 형태인 페긴터페론 람다는 인터페론 기반 치료법과 전통적으로 관련된 부작용을 최소화하면서 항바이러스 효과를 제공하는 능력에 대해 평가되고 있습니다. 표적 작용 메커니즘은 더 견딜 수 있는 치료 옵션을 제공하여 환자 결과를 개선할 수 있는 잠재력이 있습니다.

제지 / 도전

  • 델타형 간염 바이러스(HDV)에 대한 인식 부족

델타 간염 바이러스(HDV) 감염에 대한 인식이 부족한 것은 글로벌 HDV 감염 시장에 큰 제약이 됩니다. 많은 의료 서비스 제공자와 환자가 HDV 감염의 위험과 결과를 알지 못해 진단과 치료가 늦어집니다. 이러한 인식 부족으로 인해 환자는 진행된 단계에서 간 질환 진단을 받고 치료가 더 어려워지고 합병증과 사망 위험이 증가합니다.

  • 현재 치료의 부작용

Pegylated interferon-alpha has been a key therapeutic option for managing HDV due to its ability to induce a sustained viral response. However, its use is hampered by a range of debilitating side effects that can significantly impact patient adherence to the treatment regimen.

Common side effects of pegylated interferon-alpha include flu-like symptoms such as fever, chills, and muscle aches, as well as more severe issues such as fatigue, gastrointestinal disturbances, and psychological effects including depression and anxiety. These side effects can be distressing for patients, often leading to reduced quality of life and difficulty in maintaining consistent treatment. The severity of these adverse effects can discourage patients from completing their prescribed course of therapy, resulting in suboptimal treatment outcomes and potential disease progression.

Recent Developments

  • In September 2024, Gilead Sciences, Inc. and Genesis Therapeutics have formed a strategic collaboration to discover and develop novel therapies using advanced AI-driven drug discovery technologies. This partnership aims to accelerate the creation of innovative treatments, enhancing Gilead's pipeline and strengthening its position in the competitive biopharma industry
  • In March 2024, Gilead Sciences Inc. completed the acquisition of CymaBay Therapeutics, gaining access to innovative therapies for liver and rare diseases. This acquisition expands Gilead’s research portfolio and strengthens its pipeline, enhancing its capacity to address unmet medical needs. The acquisition of CymaBay provides Gilead with promising new drug candidates and expertise in liver and rare diseases, boosting its research capabilities and expanding its therapeutic offerings
  • In March 2024, Gilead Sciences, Inc. and Merus have announced a collaboration to discover novel antibody-based trispecific T-cell engagers, aiming to enhance cancer immunotherapy. This partnership combines Gilead’s expertise with Merus’ innovative technology to develop advanced treatments for cancer
  • In March 2024, Alnylam Pharmaceuticals launched the Family Health History Road Trip to promote discussions on hereditary ATTR (hATTR) amyloidosis. Genealogist Bernice Bennett traveled cross-country to highlight the importance of family health history for earlier diagnosis

Global Hepatitis Delta Virus (HDV) Infection Market Scope

The global Hepatitis Delta Virus (HDV) infection market is segmented into nine notable segments based on type, treatment, drug type, route of administration, age group, gender, transmission, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

  • Acute Hepatitis D
  •  Chronic Hepatitis D

On the basis of type, the market is segmented into acute hepatitis D, chronic hepatitis D.

Treatment

  • Surgery (Liver Transplant)
  • Medication

On the basis of treatment, the market is segmented into surgery (liver transplant) and medication.

Drug Type

  • Branded
  • Generic

On the basis of drug type, the market is segmented into branded and generic.

Route of Administration

  • Oral
  • Parenteral

On the basis of route of administration, the market is segmented into oral and parenteral.

Age group

  • Adults
  •  Geriatric
  •  Pediatric

On the basis of age group, the market is segmented into adults, geriatric, and pediatric.

Gender

  • Female
  •  Male

On the basis of gender, the market is segmented into female and male.

Transmission

  • Contaminated Needles
  •  Exposure to Infected Blood
  •  Blood and Plasma Product Transfusion
  •  Others

On the basis of transmission, the market is segmented into contaminated needles, exposure to infected blood, blood and plasma product transfusion and others.

End User

  • Hospitals
  •  Specialty Clinics
  •  Home Care Setting
  •  Research Institutes and Academic Centers
  •  Ambulatory Surgical Centers
  •  Others

On the basis of end user, the market is segmented into hospitals, specialty clinics, home care setting, research institutes and academic centers, ambulatory surgical centers, and others.

Distribution Channel

  • Direct Tender
  •  Retail Sales
  • Others

On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.

Global Hepatitis Delta Virus (HDV) Infection Market Regional Analysis/Insights

The global Hepatitis Delta Virus (HDV) infection market is segmented into nine notable segments based on type, treatment, route of administration, dosage form, age group, gender, transmission, end user, and distribution channel.

The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Switzerland, Russia, Belgium, Turkey, Denmark, Sweden, Poland, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Singapore, Philippines, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Bahrain, Kuwait, Oman, Qatar, and Rest of Middle East and Africa.

Europe is expected to dominate the global Hepatitis Delta (HDV) infection market, due to the high prevalence of HDV in countries such as Russia, Ukraine, and Eastern European nations, where it is a major public health concern and drives demand for diagnostic and treatment solutions. Germany is expected to dominate Europe region due to advances in diagnostic technologies. China is expected to dominate Asia-Pacific region due to ongoing research and development initiatives. U.S. is expected to dominate North America region due to increase in healthcare expenditure.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 대형 서비스 회사의 존재 및 가용성과 지역 및 국내 플레이어와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제와 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

델타형 간염 바이러스(HDV) 감염 시장

경쟁 환경 및 글로벌 델타형 간염(HDV) 감염 시장 점유율 분석

글로벌 델타 간염(HDV) 감염 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 응용 프로그램 우세, 제품 유형 수명선 곡선입니다. 제공된 위의 데이터 포인트는 회사가 시장에 집중하는 것과만 관련이 있습니다.

시장에서 활동하는 주요 기업으로는 Gilead Sciences, Inc., Genentech, Inc., Eiger BioPharmaceuticals, Johnson & Johnson Services, Inc., Assembly Biosciences, Inc., PharmaEssentia Corporation, Vir Biotechnology, Inc., Huahui Health Ltd., Replicor, GlobeImmune Inc., Alnylam Pharmaceuticals, Inc. 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTER FIVE FORCES

4.3 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET

4.4 DISTRIBUTION OF PRODUCTS BY PHASE

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING PREVALENCE OF HEPATITIS

6.1.2 INCREASE IN HEALTHCARE EXPENDITURE

6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES

6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES

6.2 RESTRAINTS

6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV)

6.2.2 HIGH COST OF TREATMENT

6.3 OPPORTUNITIES

6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT

6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES

6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS

6.4 CHALLENGES

6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS

6.4.2 SLOW REGULATORY APPROVALS

7 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE

7.1 OVERVIEW

7.2 ACUTE HEPATITIS D

7.3 CHRONIC HEPATITIS D

8 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT

8.1 OVERVIEW

8.2 SURGERY (LIVER TRANSPLANT)

8.3 MEDICATION

8.3.1 APPROVED THERAPIES

8.3.1.1 PEGYLATED INTERFERON ALPHA

8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE)

8.3.2 EMERGING THERAPIES

9 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM

9.1 OVERVIEW

9.2 TABLET

9.3 CAPSULE

9.4 INJECTABLE

10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE

10.1 OVERVIEW

10.2 BRANDED

10.3 GENERIC

11 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 CAPSULE

11.2.3 OTHERS

11.3 PARENTERAL

12 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER

12.1 OVERVIEW

12.2 FEMALE

12.3 MALE

13 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP

13.1 OVERVIEW

13.2 ADULTS

13.3 GERIATRIC

13.4 PEDIATRIC

14 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION

14.1 OVERVIEW

14.2 CONTAMINATED NEEDLES

14.3 EXPOSURE TO INFECTED BLOOD

14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION

14.5 OTHERS

15 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECIALTY CENTERS

15.4 HOME CARE SETTING

15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS

15.6 AMBULATORY SURGICAL CENTERS

15.7 OTHERS

16 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

16.3.1 HOSPITAL PHARMACY

16.3.2 RETAIL PHARMACY

16.3.3 ONLINE PHARMACY

16.4 OTHERS

17 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION

17.1 OVERVIEW

17.2 EUROPE

17.2.1 GERMANY

17.2.2 FRANCE

17.2.3 U.K

17.2.4 ITALY

17.2.5 SPAIN

17.2.6 NETHERLANDS

17.2.7 SWITZERLAND

17.2.8 RUSSIA

17.2.9 BELGIUM

17.2.10 TURKEY

17.2.11 DENMARK

17.2.12 SWEDEN

17.2.13 POLAND

17.2.14 NORWAY

17.2.15 FINLAND

17.2.16 REST OF EUROPE

17.3 MIDDLE EAST AND AFRICA

17.4 NORTH AMERICA

17.4.1 U.S.

17.4.2 CANADA

17.4.3 MEXICO

17.5 ASIA PACIFIC

17.6 SOUTH AMERICA

18 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: GLOBAL

18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

18.3 COMPANY SHARE ANALYSIS: EUROPE

18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 GILEAD SCIENCES, INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PIPELINE PRODUCT

20.1.5 RECENT DEVELOPMENTS

20.2 GENENTECH, INC.

20.2.1 COMPANY SNAPSHOT

20.2.2 PRODUCT PORTFOLIO

20.2.3 RECENT DEVELOPMENT

20.3 ALNYLAM PHARMACEUTICALS, INC.

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 PIPELINE PRODUCT

20.3.4 RECENT DEVELOPMENTS

20.4 ASSEMBLY BIOSCIENCES, INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 PIPELINE PRODUCT

20.4.4 RECENT DEVELOPMENTS

20.5 EIGER BIOPHARMACEUTICALS

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 PIPELINE PRODUCT

20.5.6 RECENT DEVELOPMENT

20.6 GLOBEIMMUNE INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 PIPELINE PRODUCT

20.6.3 RECENT DEVELOPMENT

20.7 HUAHUI HEALTH LTD.

20.7.1 COMPANY SNAPSHOT

20.7.2 PIPELINE PRODUCT

20.7.3 RECENT DEVELOPMENT

20.8 JOHNSON & JOHNSON SERVICES, INC.

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PIPELINE PRODUCT

20.8.4 RECENT DEVELOPMENT

20.9 PHARMAESSENTIA CORPORATION

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PIPELINE PRODUCT

20.9.4 RECENT DEVELOPMENT

20.1 REPLICOR

20.10.1 COMPANY SNAPSHOT

20.10.2 PIPELINE PRODUCT

20.10.3 RECENT DEVELOPMENTS

20.11 VIR BIOTECHNOLOGY, INC.

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANALAYSIS

20.11.3 PRODUCT PIPELINE

20.11.4 RECENT DEVELOPMENTS

21 QUESTIONNAIRE

22 RELATED REPORTS

표 목록

TABLE 1 EMERGING NOVEL THERAPIES FOR HDV

TABLE 2 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 3 GLOBAL ACUTE HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL CHRONIC HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 6 GLOBAL SURGERY (LIVER TRANSPLANT) IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL TABLET IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL CAPSULE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL INJECTABLE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL BRANDED IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL GENERIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL PARENTERAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 22 GLOBAL FEMALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 GLOBAL MALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 24 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 25 GLOBAL ADULTS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 26 GLOBAL GERIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 27 GLOBAL PEDIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 28 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 29 GLOBAL CONTAMINATED NEEDLES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 30 GLOBAL EXPOSURE TO INFECTED BLOOD IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 31 GLOBAL BLOOD AND PLASMA PRODUCT TRANSFUSION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 32 GLOBAL OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 33 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 34 GLOBAL HOSPITALS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 35 GLOBAL SPECIALTY CLINICS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 36 GLOBAL HOME CARE SETTING IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 37 GLOBAL RESEARCH INSTITUTES AND ACADEMIC CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 38 GLOBAL AMBULATORY SURGICAL CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 39 GLOBAL OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 40 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 41 GLOBAL DIRECT TENDER IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 42 GLOBAL RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 43 GLOBAL RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 44 GLOBAL OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 45 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 46 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 47 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 48 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 49 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 50 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 51 EUROPE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 53 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 54 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 55 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 56 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 57 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 58 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 59 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 60 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 61 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 62 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 64 GERMANY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 GERMANY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 67 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 68 GERMANY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 70 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 71 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 72 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 73 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 74 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 75 GERMANY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 78 FRANCE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 79 FRANCE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 80 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 81 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 82 FRANCE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 84 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 85 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 86 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 87 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 88 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 89 FRANCE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 92 U.K. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 U.K. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 94 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 95 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 96 U.K. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 97 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 98 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 99 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 100 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 101 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 102 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 103 U.K. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 106 ITALY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 107 ITALY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 108 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 109 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 110 ITALY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 112 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 113 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 114 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 115 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 116 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 117 ITALY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 119 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 120 SPAIN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 121 SPAIN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 122 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 124 SPAIN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 126 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 127 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 128 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 129 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 130 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 131 SPAIN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 132 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 134 NETHERLANDS MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 NETHERLANDS APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 136 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 138 NETHERLANDS ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 139 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 140 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 141 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 142 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 143 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 144 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 145 NETHERLANDS RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 146 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 147 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 148 SWITZERLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 SWITZERLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 150 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 151 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 152 SWITZERLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 154 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 155 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 156 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 157 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 158 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 159 SWITZERLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 160 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 161 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 162 RUSSIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 163 RUSSIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 164 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 165 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 166 RUSSIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 168 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 169 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 170 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 171 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 172 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 173 RUSSIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 174 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 175 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 176 BELGIUM MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 177 BELGIUM APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 178 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 180 BELGIUM ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 181 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 182 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 183 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 184 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 185 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 186 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 187 BELGIUM RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 188 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 189 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 190 TURKEY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 191 TURKEY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 193 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 194 TURKEY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 196 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 197 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 198 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 199 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 200 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 201 TURKEY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 202 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 203 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 204 DENMARK MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 DENMARK APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 207 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 208 DENMARK ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 209 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 210 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 211 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 212 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 213 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 214 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 215 DENMARK RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 216 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 218 SWEDEN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 SWEDEN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 220 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 221 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 222 SWEDEN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 223 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 224 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 225 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 226 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 227 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 228 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 229 SWEDEN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 230 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 231 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 232 POLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 POLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 234 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 235 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 236 POLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 238 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 239 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 240 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 241 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 242 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 243 POLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 246 NORWAY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 247 NORWAY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 248 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 249 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 250 NORWAY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 251 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 252 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 253 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 254 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 255 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 256 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 257 NORWAY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 258 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 259 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 260 FINLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 261 FINLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 262 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 263 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 264 FINLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 265 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 266 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 267 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 268 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 269 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 270 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 271 FINLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 272 REST OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 273 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 274 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 275 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 276 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 277 MIDDLE EAST AND AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 278 MIDDLE EAST AND AFRICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 279 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 280 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 281 MIDDLE EAST AND AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 282 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 283 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 284 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 285 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 286 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 287 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 288 MIDDLE EAST AND AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 289 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 290 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 291 SAUDI ARABIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 292 SAUDI ARABIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 293 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 294 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 295 SAUDI ARABIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 297 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 298 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 299 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 300 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 301 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 302 SAUDI ARABIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 303 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 304 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 305 SOUTH AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 SOUTH AFRICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 307 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 308 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 309 SOUTH AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 310 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 311 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 312 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 313 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 314 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 315 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 316 SOUTH AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 317 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 318 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 319 U.A.E MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 320 U.A.E APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 321 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 322 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 323 U.A.E ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 324 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 325 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 326 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 327 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 328 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 329 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 330 U.A.E RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 332 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 333 EGYPT MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 EGYPT APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 335 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 336 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 337 EGYPT ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 338 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 339 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 340 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 341 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 342 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 343 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 344 EGYPT RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 345 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 346 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 347 BAHRAIN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 348 BAHRAIN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 349 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 350 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 351 BAHRAIN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 352 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 353 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 354 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 355 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 356 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 357 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 358 BAHRAIN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 359 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 360 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 361 KUWAIT MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 362 KUWAIT APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 363 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 364 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 365 KUWAIT ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 366 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 367 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 368 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 369 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 370 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 371 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 372 KUWAIT RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 373 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 374 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 375 OMAN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 376 OMAN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 379 OMAN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 380 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 381 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 382 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 383 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 384 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 385 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 386 OMAN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 387 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 388 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 389 QATAR MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 390 QATAR APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 391 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 392 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 393 QATAR ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 394 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 395 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 396 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 397 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 398 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 399 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 400 QATAR RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 401 REST OF MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 402 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 403 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 404 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 405 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 406 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 407 NORTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 408 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 409 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 410 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 411 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 412 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 413 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 414 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 415 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 416 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 417 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 418 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 419 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 420 U.S. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 421 U.S. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 422 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 423 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 424 U.S. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 425 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 426 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 427 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 428 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 429 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 430 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 431 U.S. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 432 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 433 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 434 CANADA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 435 CANADA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 436 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 437 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 438 CANADA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 439 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 440 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 441 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 442 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 443 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 444 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 445 CANADA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 446 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 447 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 448 MEXICO MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 449 MEXICO APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 450 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 451 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 452 MEXICO ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 453 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 454 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 455 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 456 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 457 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 458 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 459 MEXICO RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 460 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 461 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 462 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 463 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 464 ASIA-PACIFIC MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 465 ASIA-PACIFIC APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 466 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 467 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 468 ASIA-PACIFIC ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 469 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 470 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 471 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 472 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 473 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 474 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 475 ASIA-PACIFIC RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 476 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 477 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 478 CHINA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 479 CHINA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 480 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 481 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 482 CHINA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 483 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 484 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 485 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 486 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 487 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 488 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 489 CHINA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 490 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 491 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 492 JAPAN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 493 JAPAN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 494 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 495 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 496 JAPAN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 497 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 498 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 499 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 500 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 501 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 502 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 503 JAPAN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 504 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 505 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 506 INDIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 507 INDIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 508 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 509 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 510 INDIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 511 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 512 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 513 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 514 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 515 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 516 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 517 INDIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 518 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 519 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 520 SOUTH KOREA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 521 SOUTH KOREA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 522 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 523 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 524 SOUTH KOREA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 525 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 526 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 527 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 528 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 529 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 530 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 531 SOUTH KOREA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 532 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 533 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 534 AUSTRALIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 535 AUSTRALIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 536 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 537 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 538 AUSTRALIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 539 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 540 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 541 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 542 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 543 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 544 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 545 AUSTRALIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 546 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 547 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 548 THAILAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 549 THAILAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 550 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 551 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 552 THAILAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 553 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 554 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 555 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 556 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 557 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 558 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 559 THAILAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 560 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 561 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 562 MALAYSIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 563 MALAYSIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 564 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 565 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 566 MALAYSIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 567 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 568 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 569 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 570 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 571 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 572 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 573 MALAYSIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 574 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 575 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 576 INDONESIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 577 INDONESIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 578 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 579 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 580 INDONESIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 581 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 582 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 583 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 584 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 585 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 586 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 587 INDONESIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 588 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 589 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 590 SINGAPORE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 591 SINGAPORE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 592 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 593 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 594 SINGAPORE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 595 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 596 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 597 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 598 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 599 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 600 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 601 SINGAPORE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 602 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 603 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 604 PHILIPPINES MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 605 PHILIPPINES APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 606 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 607 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 608 PHILIPPINES ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 609 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 610 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 611 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 612 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 613 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 614 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 615 PHILIPPINES RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 616 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 617 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 618 NEW ZEALAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 619 NEW ZEALAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 620 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 621 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 622 NEW ZEALAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 623 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 624 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 625 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 626 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 627 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 628 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 629 NEW ZEALAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 630 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 631 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 632 VIETNAM MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 633 VIETNAM APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 634 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 635 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 636 VIETNAM ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 637 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 638 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 639 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 640 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 641 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 642 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 643 VIETNAM RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 644 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 645 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 646 TAIWAN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 647 TAIWAN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 648 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 649 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 650 TAIWAN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 651 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 652 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 653 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 654 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 655 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 656 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 657 TAIWAN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 658 REST OF ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 659 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 660 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 661 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 662 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 663 SOUTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 664 SOUTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 665 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 666 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 667 SOUTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 668 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 669 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 670 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 671 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 672 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 673 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 674 SOUTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 675 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 676 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 677 BRAZIL MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 678 BRAZIL APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 679 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 680 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 681 BRAZIL ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 682 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 683 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 684 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 685 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 686 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 687 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 688 BRAZIL RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 689 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 690 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 691 ARGENTINA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 692 ARGENTINA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 693 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 694 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 695 ARGENTINA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 696 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 697 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 698 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 699 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 700 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 701 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 702 ARGENTINA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 703 REST OF SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

그림 목록

FIGURE 1 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION

FIGURE 2 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: END USER COVERAGE GRID

FIGURE 8 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION

FIGURE 11 TWO SEGMENTS COMPRISE THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE

FIGURE 12 GROWING PREVALENCE OF HEPATITIS IS DRIVING THE GROWTH OF THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET FROM 2024 TO 2031

FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN 2024 AND 2031

FIGURE 14 EUROPE IS EXPECTED TO DOMINATE THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 15 EUROPE IS THE FASTEST-GROWING REGION FOR GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET

FIGURE 17 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2023

FIGURE 18 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2024-2031 (USD THOUSAND)

FIGURE 19 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 20 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 21 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2023

FIGURE 22 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)

FIGURE 23 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)

FIGURE 24 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 25 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2023

FIGURE 26 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)

FIGURE 27 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, CAGR (2024-2031)

FIGURE 28 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 29 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2023

FIGURE 30 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 31 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 32 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 33 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 34 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 35 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 36 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 37 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER,2023

FIGURE 38 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, 2024-2031 (USD THOUSAND)

FIGURE 39 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 40 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, LIFELINE CURVE

FIGURE 41 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2023

FIGURE 42 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)

FIGURE 43 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, CAGR (2024-2031)

FIGURE 44 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 45 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2023

FIGURE 46 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2024-2031 (USD THOUSAND)

FIGURE 47 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, CAGR (2024-2031)

FIGURE 48 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, LIFELINE CURVE

FIGURE 49 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2023

FIGURE 50 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 51 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, CAGR (2024-2031)

FIGURE 52 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, LIFELINE CURVE

FIGURE 53 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 54 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 55 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 56 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 57 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SNAPSHOT (2023)

FIGURE 58 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

FIGURE 59 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

FIGURE 60 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

FIGURE 61 AISA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The market is segmented based on Global Hepatitis Delta Virus (HDV) Infection Market, By Type (Acute Hepatitis D and Chronic Hepatitis D), Treatment (Surgery (Liver Transplant) and Medication), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral), Age Group (Adults, Geriatric, and Pediatric), Gender (Female and Male), Transmission (Contaminated Needles, Exposure to Infected Blood, Blood and Plasma Product Transfusion, and Others), End User (Hospitals, Specialty Clinics, Home Care Setting, Research Institutes and Academic Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031 .
The Global Hepatitis Delta Virus Hdv Infection Market size was valued at USD 47.34 USD Million in 2023.
The Global Hepatitis Delta Virus Hdv Infection Market is projected to grow at a CAGR of 4.8% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Switzerland, Russia, Belgium, Turkey, Denmark, Sweden, Poland, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Singapore, Philippines, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Bahrain, Kuwait, Oman, Qatar, and Rest of Middle East and Africa.